Skip to main content

Table 1 Patient demographics and clinical characteristics

From: Establishment and validation of a predictive nomogram model for non-small cell lung cancer patients with chronic hepatitis B viral infection

  Primary cohort Validation cohort
n = (141) n = (89)
Characteristic No. (%) No. (%)
 Gender
  Male 72 (51.1%) 50 (56.2%)
  Female 69 (48.9%) 39 (43.8%)
 Age (years)
  ≤ 42 19 (13.5%) 11 (12.4%)
  > 42 122 (86.5%) 78 (87.6%)
 Family history
  Yes 36 (25.5%) 18 (20.2%)
  No 105 (74.5%) 71 (79.8%)
 Smoking behaviour
  Yes 84 (59.6%) 50 (56.2%)
  No 57 (40.4%) 39 (43.8%)
 BMI
  ≥ 25 30 (21.3%) 14 (15.7%)
  18.5 ≤ BMI < 25 103 (73.0%) 65 (73.0%)
  < 18.5 8 (5.7%) 10 (11.3%)
 TNM stagea
  I 31 (22.0%) 23 (25.8%)
  II 17 (12.1%) 6 (6.7%)
  III 53 (37.6%) 34 (38.2%)
  IV 40 (28.3%) 26 (29.3%)
 Size (cm)b
  ≤ 6.3 122 (86.5%) 70 (78.7%)
  > 6.3 19 (13.5%) 19 (21.3%)
 Treatment
  Surgery 37 (26.2%) 21 (23.6%)
  Radiotherapy/chemotherapy 47 (33.3%) 31 (34.8%)
  Surgery and radiotherapy/chemotherapy 49 (34.8%) 25 (28.1%)
  Other 8 (5.7%) 12 (13.5%)
 ALT (U/L)
  ≤ 12.5 15 (10.6%) 11 (12.4%)
  > 12.5 126 (89.4%) 78 (87.6%)
 AST (U/L)
  ≤ 22.0 73 (51.8%) 45 (50.1%)
  > 22.0 68 (48.2%) 44 (49.9%)
 SLR
  ≤ 1.24 102 (72.3%) 61 (68.5%)
  > 1.24 39 (27.7%) 28 (31.5%)
 APOAI (g/L)
  ≤ 1.17 56 (39.7%) 39 (43.8%)
  > 1.17 85 (60.3%) 50 (56.2%)
 APOB (g/L)
  ≤ 0.99 92 (65.2%) 50 (56.2%)
  > 0.99 49 (34.8%) 39 (43.8%)
 ALP (U/L)
  ≤ 82.9 96 (68.1%) 51 (57.3%)
  > 82.9 45 (31.9%) 38 (42.7%)
 ALB (g/L)
  ≤ 40.1 108 (76.6%) 62 (69.7%)
  > 40.1 33 (23.4%) 27 (30.3%)
 GGT (U/L)
  ≤ 44.2 117 (83.0%) 72 (80.9%)
  > 44.2 24 (17.0%) 17 (19.1%)
 LDH (U/L)
  ≤ 245.6 125 (88.7%) 77 (86.5%)
  > 245.6 16 (11.2%) 12 (13.5%)
 TBIL (μmol/L)
  ≤ 13.6 113 (80.1%) 61 (68.5%)
  > 13.6 28 (19.9%) 28 (31.5%)
 DBIL (μmol/L)
  ≤ 3.3 67 (47.5%) 38 (42.7%)
  > 3.3 74 (52.5%) 51 (57.2%)
  1. BMI body mass index, TNM pathological tumour node metastasis stage, ALT alanine transaminase, AST aspartate aminotransferase, SLR AST-to-ALT ratio, APOAI apolipoprotein AI, APOB apolipoprotein B, ALP alkaline phosphatase, ALB albumin, GGT glutamyl transpeptidase, LDH lactic dehydrogenase, TBIL total bilirubin, DBIL direct bilirubin
  2. aTNM stage was classified according to the AJCC 7th TNM staging system
  3. bThe tumor maximum diameter